Some of the conditions we are targeting are fatal; others are currently incurable, and all greatly affect quality of life.
Ceria Therapeutics is developing drugs to address runaway inflammation at the site of disease. We see tremendous potential to resolve some of humankind’s most vexing afflictions. Multiple products in our pipeline are positioned to enter clinical trials. Our current targets include:
ARDS
ARDS is the leading cause of death for those infected with COVID-19. The mortality rate for ARDS is 30%-50%. In critical cases, survivors cannot breathe without mechanical assistance; recovery can take years.
ALI
Long-term complications of ALI include decreased lung capacity, muscle weakness, and psychological distress, all of which greatly affects
quality of life.
IBD
IBD can cause weight gain; when combined with unpredictable and frequent needs for elimination, self-esteem issues often result and lead to anxiety, depression, and suicidal ideation.
DFUs
DFUs are the most common reason for hospitalization of diabetic patients and the leading cause of non-traumatic amputation. Losing a limb can hasten the decline of
elderly patients.
01
ARDS
Acute Respiratory Distress Syndrome [ARDS] is a severe and life-threatening lung condition. ARDS is characterized by rapid onset of widespread inflammation in the lungs resulting in extreme difficulty breathing and maintaining body oxygen levels. ARDS typically occurs as a result of an underlying injury or illness, such as pneumonia, sepsis, trauma, inhalation of harmful substances, or severe respiratory infections. Short-term consequences of ARDS include alveolar collapse and pulmonary inflammation. Long-term consequences of ALI include reduced pulmonary function and lung fibrosis.
Our Solution
Ceria Tx is developing a drug for use in hospitalized and ICU patients that will be the first to eliminate the inflammation associated with ARDS.
02
Acute lung injuries
Breathing in toxic chemicals, infectious pathogens (viruses, bacteria, fungi), smoke, or hot gases as well as chest and airway trauma can cause direct damage to the lungs and trigger acute lung injury [ALI]. This type of injury is commonly seen in cases of traumatic injury to the torso, smoke inhalation during fires, chemical inhalation during industrial accidents, and multiple types of battlefield injury. Regardless of the way lungs become injured, recovery can be difficult. In severe cases, an affected individual with ALI may progress to ARDS.
Our Solution
Ceria Tx is developing an inhalation therapeutic for administration by first responders and emergent/urgent care providers that prevents unregulated inflammation and resolves the consequences of lung injuries hours after exposure.
03
IBD
Inflammatory Bowel Disease is a group of chronic inflammatory conditions primarily affecting the gastrointestinal tract. The exact cause of IBD is unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors. Chronic inflammation results in the body’s immune system mistakenly attacking its tissues. While IBD is not fatal, it is painful and disruptive to an affected individual’s quality of life. Currently, there is no cure.
Our Solution
Ceria Tx is developing a pair of drugs to target the underlying cause of IBD-associated inflammation and control the inflammatory response within the digestive tract.
04
Non-Healing Wounds
These open sores are otherwise known as diabetic foot ulcers [DFU]. They are a severe complication of diabetes. If left untreated, foot ulcers can become infected and spread to deeper tissues, bones, and joints, which may result in serious complications such as cellulitis (skin infection), osteomyelitis (bone infection), or even gangrene (tissue death).
Our Solution
Ceria Tx is developing an injectable drug and a topical agent to arrest inflammation associated with DFU.
Our drugs are developed to maximize safety and efficacy for each condition. Still, they are unified in their ability to regulate the inflammatory response at the infection site and restore natural healing.
CONTACT US
OUR ADDRESS
Ceria Therapeutics, Inc
1230 N Cherry Ave, BSRL 329
Tucson, AZ 85721